Roche’s PATHWAY HER2 (4B5) test helps identify patients with HER2-ultralow breast cancer, who may be eligible for targeted ...

As seen in the DESTINY-Breast06 trial, approximately 20-25 percent of hormone receptor (HR)-positive, HER2-negative breast ...

Author, speaker and health content creator Dr Liz O’Riordan shares her journey from consultant breast surgeon to cancer ...

Basel: Roche has announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion for the PATHWAY ...

Time is important with a cancer diagnosis so that treatment can be started early before cancer spreads.” - Dr. Hazem Abdel Samie, Managing Director of MSD Egypt ClusterCAIRO, EGYPT, January 31, 2025 ...

Major medical initiatives to bolster Saudi Arabia’s healthcare sector have been unveiled this week, including a state-of-the-art oncology center and a huge ...

Her employer said a contract is only ended when "all other options have been exhausted and a robust process has been followed" ...

Roche has announced that the FDA has expanded the approval of its PATHWAY® HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test to identify HE ...

Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...

Media Release Marking Immutep's transition to a Phase III biotech, the Company's pivotal TACTI-004 trial in first-line non-small cell lung cancer (1L NSCLC) received first regulatory approvalMature da ...

Q4 2024 Earnings Call Transcript January 31, 2025 Novartis AG beats earnings expectations. Reported EPS is $1.98, ...

On 30 January 2025, over 100 healthcare professionals and researchers gathered at Medisch Spectrum Twente for the presentation of the Pioneers in ...